Related Experiment Video
Updated: May 27, 2026
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
[Rituximab for the treatment of ANCA associated vasculitis: the future today?]
Marco A Alba1, Luis F Flores-Suárez
1Unidad de investigación en Vasculitis, Servicio de Enfermedades Autoinmunes Sistémicas, Hospital Clínic, Barcelona, España.
Abstract:
Since cyclophosphamide was introduced for the treatment of ANCA-associated vasculitis, the mortality of these diseases has decreased considerably. However, such treatment is related to acute and chronic serious adverse effects, which contribute to the morbidity and mortality of such diseases. Therefore, one of the main challenges in the treatment of such conditions is to find newer and effective therapies with a safer profile. Rituximab (RTX), an anti-CD20 monoclonal antibody stands at the top of new options for the treatment of ANCA-associated vasculitis, and is the strongest candidate to establish itself as a first choice therapeutic agent. Here, we review the rationale of RTX treatment in ANCA-associated small vessel vasculitis, and the current evidence of both its efficacy and toxicity.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Rheumatic Heart Disease III: Medical Management
Myocarditis III: Medical Management
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune system...
Pericarditis III: Medical Management
Nephrotic Syndrome II : Assessment and Medical Management
